| Autor: |
Ahmad, Syed A, Shaheen, Raymond M, Liu, Wenbiao, Jung, Young D, Takahashi, Yutaka, Akagi, Yoshito, Reinmuth, Niels, Fan, Fan, Ellis, Lee M |
| Zdroj: |
Emerging Therapeutic Targets; June 2000, Vol. 4 Issue: 3 p347-359, 13p |
| Abstrakt: |
Folkman’s discovery that the growth and spread of tumours depend on angiogenesis has created new avenues of research designed to better understand cancer biology and facilitate the development of new therapeutic strategies. The survival and metastasis of tumours depend on a shift in the normal balance among myriad endogenous angiogenic and anti-angiogenic factors in favour of increased angiogenesis. Several growth factors that regulate angiogenesis in colon cancer have been identified, including the pro-angiogenic factors vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF) and the anti-angiogenic factor, thrombospondin. A thorough understanding of the roles that these factors play in the angiogenic process has led to the development of agents intended to inhibit tumour angiogenesis. However, the complexity and redundancy of the angiogenic process continue to present substantial challenges to the development of anticancer therapies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
